TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06800326

Intervention type: DIAGNOSTIC_TEST
Intervention: MRE Scan
Description: Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
Study: NCT06163989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TheaLoz Duo Eyedrop
Description: TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheaLoz Duo Eyedrop
Description: TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
Study: NCT06801626

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Famotidine and 4% topical cromolyn sodium
Description: Patients will be instructed to take a 20mg famotidine capsule twice daily, and to use the lotion (4% cromolyn sodium) twice daily.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Famotidine and 4% topical cromolyn sodium
Description: Patients will be instructed to take a 20mg famotidine capsule twice daily, and to use the lotion (4% cromolyn sodium) twice daily.
Study: NCT06800430

Intervention type: RADIATION
Intervention: Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography
Description: Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), within 28 days (+/- 28 days) of their CABG surgery and again at 12 month follow-up.

Intervention type: RADIATION
Intervention: Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography
Description: Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), prior to their clinical invasive coronary angiography.
Study: NCT06801366

Intervention type: DIAGNOSTIC_TEST
Intervention: Parent-recorded smartphone video clips
Description: Parents will record smartphone video clips of their child asleep, which will be scored by pediatric sleep physicians for presence of moderate-severe OSA. Children will then undergo clinically indicated polysomnography (PSG). Video clips will be evaluated for diagnostic accuracy, with PSG as the gold standard.
Study: NCT06801457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NBO
Description: NBO will be conducted with inhalation of 100% oxygen.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Best medical care
Study: NCT06801730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome combined with bevacizumab
Description: Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;
Study: NCT06801548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esthetic crown lengthening surgery
Description: Esthetic crown lengthening surgery using mock-up based guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esthetic crown lengthening surgery using Digital guide
Description: 1- Int
Study: NCT06797830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllCore
Description: AllCore360° is a novel core-strengthening machine intervention designed to target trunk muscles through gravity by means of high-intensity constant velocity rotating exercise (allcore360.com).~AllCore360° is systematic, consistent and designed for use over time. The core is strengthened because a patient's core muscles are used in anterior, lateral, and posterior contractions sequentially during a single rotation (Palevo). The patient must resist gravity with the rotation as well as contract and fire isometrically to keep proper posture. Using proper posture, the patient must keep their back straight and neck neutral throughout the length of the intervention without relying on their lower body muscles at all (this is assisted by straps rendering the legs useless and by securing the pelvis in the chair).
Study: NCT06801912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Change Technique Package
Description: Behavior Change Technique 1: Goal setting (Behavior) (BCT 1.1). Goal setting for behavior is defined as setting a goal for the behavior to be achieved.~Behavior Change Technique 2: Action planning (BCT 1.4). Action planning is defined as detailing the plan of where, for how long, and at what time taking medication is going to be performed.~Behavior Change Technique 3: Self-monitoring of behavior (BCT 2.3). Self-monitoring of behavior is defined as monitoring and recording behavior.~Behavior Change Technique 4: Prompts/Cues (BCT 7.1) This BCT is defined as prompt rehearsal and repetition of the behavior in the same context repeatedly, so that the context elicits the behavior.
Study: NCT06801704

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Top Set Resistance Training
Description: Participants will receive four warm-up sets at increasingly higher resistance, followed by three sets of eight repetitions per set on six resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Power Resistance Training
Description: Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set on six power resistance-training exercises. During training participants will be allowed 1-minute rests between sets. Participants will come in person for up to 12 weeks, twice per week, for approximately 45 minutes per day.
Study: NCT06801301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: Standing in different static positions or exercising on a vibrating platform.The mechanical stimuli of vibration transmitted to the body and stimulate muscle spindles which activate the alpha motor neurons and initiates muscle contractions comparable to the ''tonic vibration reflex. The effect of WBV on the neuromuscular properties of skeletal muscles and spinal mechanisms is demonstrated by a decreased electromechanical delay.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Resistance training as a mode of exercise to promote several health benefits, including improvements in the muscle mass and strength of healthy adults.Resistance training, where muscles are required to contract against an opposing load, has been shown to be a beneficial form of rehabilitation in clinical populations prone to muscle wasting, providing stimuli to increase protein synthesis and muscle mass.
Study: NCT06800404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous HB-adMSCs
Description: Autologous HB-adMSCs
Study: NCT06801223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 25mg/kg -Durlobactam 25mg/kg
Description: 25mg/kg SUL and 25mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 25mg/kg -Durlobactam 25mg/kg
Description: 25mg/kg SUL and 25mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 25mg/kg -Durlobactam 25mg/kg
Description: 25mg/kg SUL and 25mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 25mg/kg -Durlobactam 25mg/kg
Description: 25mg/kg SUL and 25mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 25mg/kg -Durlobactam 25mg/kg
Description: 25mg/kg SUL and 25mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 25mg/kg -Durlobactam 25mg/kg
Description: 25mg/kg SUL and 25mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 20mg/kg-Durlobactam 20mg/kg
Description: 20mg/kg SUL and 20mg/kg DUR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam 20mg/kg-Durlobactam 20mg/kg
Description: 20mg/kg SUL and 20mg/kg DUR
Study: NCT06802055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus (Rapamune®)
Description: Sirolimus 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (Rapamune®)
Description: Sirolimus 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Description: Cyclosporine A 25-150 mg orally every 12 hours, with the dose adjusted based on renal function and trough concentration. For patients with normal renal function, the target trough concentration is approximately 150 ng/ml. For patients with impaired renal function, the cyclosporine A dose is reduced to 25-50 mg every 12 hours, aiming for recovery or stabilization of renal function.
Study: NCT06800872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary metabolic rehabilitation
Description: Standard in-hospital protocol of multidisciplinary metabolic rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary metabolic rehabilitation + training with WBVE
Description: Standard in-hospital protocol of multidisciplinary metabolic rehabilitation + 24 sessions (2 sessions per day) of 30 minutes each of training on a vibration platform (WBVE)
Study: NCT06802068

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whole salmon oil
Description: A minimally processed whole salmon oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod liver oil
Description: Standard, processed omega-3 cod liver oil
Study: NCT06801158

Intervention type: DRUG
Intervention: use of anticancer drugs in monotherapy or in combination therapy
Description: ICSRs involving antineoplastic or immunomodulating agents were included.

Intervention type: DRUG
Intervention: use of anticancer drugs in monotherapy or in combination therapy
Description: ICSRs involving antineoplastic or immunomodulating agents were included.
Study: NCT06801535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splint
Description: Patients will use the splint at home 3 times daily for 10 minutes per session for 3 months total.
Study: NCT06800339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: This will be administered intravenously once every 3 weeks for up to 3 cycles (i.e. 9 weeks of total systemic therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Three fractions of radiation delivered every other day, for three total days. The final dose of radiation will happen within 7 days of starting chemoimmunotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Post treatment patient will be evaluated for surgical resection
Study: NCT06801522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% xylometazoline nasal drops
Description: Xylometazoline is direct acting, non selective, adrenergic agonist binding with alpha 1\&2 receptors, used for vasoconstriction to decrease nasal bleeding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline nasal pack
Description: Adrenaline is direct acting, non selective, adrenergic agonist binding with alpha and beta receptors both, used for vasoconstriction to decrease nasal bleeding.
Study: NCT06800963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravesical Recombinant Mycobacterium (rMBCG)
Description: 19.2e8 CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, intravesical administration)
Study: NCT06800235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Simulation
Description: Nursing students in the experimental group were informed about computer-based simulation. They were also informed about the aspiration skill form and general competency scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Control grup
Description: Nursing students in the control group were informed about the standard procedure/traditional method. They were also informed about the aspiration skill form and general competency scale.
Study: NCT06801041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will recive treatment by mouth on an outpatient basis.
Study: NCT06800417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous fixation by internal cemented screw (InnoFix®)
Description: Percutaneous fixation by internal cemented screw
Study: NCT06801834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Administered intravenously
Study: NCT06801717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTP Laser Therapy
Description: Participants will receive full face treatments with 532 nm KTP laser for 3 sessions at 8-12 weeks apart. Laser therapy will be conducted in person. Each laser treatment session will last up to 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency microneedling
Description: Participants will receive unilateral facial treatments with radiofrequency microneedling device for 3 sessions at 8-12 weeks apart. Radiofrequency microneedling will be conducted in person. Each treatment session will last up to 1 hour.
Study: NCT06801639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active-tDCS treatment will consist of a constant 2mA current applied during daily 30-minute sessions with a 30 second ramp up and ramp down at the start and end of the stimulation. The anode electrode will be placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode electrode over the right DLPFC.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham-tDCS treatment will consist of the same montage as the active-tDCS but the electric current will be applied only in the first and final 30s of stimulation.
Study: NCT06800846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraosseous Morphine
Description: Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection
Description: Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.
Study: NCT06800612

Intervention type: DRUG
Intervention: Oncologic drugs administered for treatment of breast cancer
Description: Data on oncologic drugs administered for treatment of breast cancer will be recorded

Intervention type: DRUG
Intervention: Oncologic drugs administered for treatment of breast cancer
Description: Data on oncologic drugs administered for treatment of breast cancer will be recorded

Intervention type: DRUG
Intervention: Oncologic drug administered for treatment of gynecologic cancer
Description: Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded

Intervention type: DRUG
Intervention: Oncologic drug administered for treatment of gynecologic cancer
Description: Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
Study: NCT06434909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytalux™ (pafolacianine) for fluorescent imaging
Description: Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status.~This is used in conjunction with appropriate imaging system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Surgery
Description: prostatectomy using appropriate imaging system
Study: NCT06797869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CagriSema (Cagrilintide B and Semaglutide I)
Description: Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Description: Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Study: NCT05190172

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy either with protons or photons

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy either with protons or photons
Study: NCT06801769

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-peptide
Description: Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT).
Study: NCT06799572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Hands will be washed with hand soap and rubbed with disinfectant before the procedure.~* The head of the bed is raised by 30°-45° in the incubator.~* The baby is placed face down.~* Vaseline is applied to the hands.~* The 15 minute session will consist of three 5 minute phases. Phase 1 will be tactile stimulation phase, Phase 2 will be kinesthetic stimulation and Phase 3 will be I Love You technique.~* In the tactile stimulation phase, the infant is turned to the prone position and a stroking motion (12 strokes in approximately 5 seconds) will be applied with moderate pressure in 1-minute intervals, from the top of the head to the neck and back to the top of the head, from the neck to the shoulder, from the neck to the shoulder, from the upper back to the waist and back to the upper back, from the thigh to the foot and both legs, from the shoulder to the hand and from both arms to the shoulder.~* In the kinesthetic stimulation phase, the infant is placed in the supine position and eac
Study: NCT06802081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
Study: NCT06800781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolonged treatment with posterior pericardial chest tube plus standard care
Description: Prolonged treatment with posterior pericardial chest tube plus standard care All patients will receive chest tubes based on each surgeon's preference. Usually, 1 or 2 tubes are inserted in the mediastinum, and 1 is inserted into each open pleural cavity. Patients in the intervention arm will receive an additional posterior 20Ch chest tube. In cases where the surgeon routinely inserts 2 mediastinal chest tubes, they will use 1-2 anterior mediastinal tubes in the intervention group, based on their preference. The posterior chest tube will be positioned between the inferior aspect of the heart and the pericardium and connected to an active suction system per routine. Once the remaining chest tubes are extracted, the posterior chest tube will remain positioned in the pericardium and be reconnected from active suction to a collection bag for passive drainage. The chest tube will be removed on postoperative Day 3 or when chest tube output is \<50 mL/24 h.
Study: NCT06800495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THALEA (Thalassemia Education and Awareness) Kit
Description: By using the opinions obtained by the experts, THALEA's content will then be designed using the Theory of Planned Behaviour (TPB) by Ajzen and Fishbein.~Development of THALEA:~• Language: Malay and English.~• Contents of the THALEA kit: i. PowerPoint or Canva presentations with discussion prompts (softcopy form) ii. Links/joining codes to free educational game platforms such as Kahoot or Quizziz iii. Videos - convey messages on thalassemia awareness and screening importance.~iv. Illustrated guides/brochures - to provide step-by-step tutorials on how to get thalassemia screening in both the public and private healthcare.~• Developer would be the main researcher with aid from: i. Illustrator ii. Video graphic designer iii. Influencers~• Delivery of THALEA to students by: i. Medical personnel

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic thalassemia and family health education
Description: They are basic family health education in which it is the usual family health education given by the MOH, usually delivered by a medical officer, to fourth form students at government schools prior to the thalassemia screening programme. It will consist of a delivery of a PowerPoint presentation and videos, that will be obtained from government public health clinics in Klang Valley.
Study: NCT06801795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AviClear
Description: Participants will receive as many as 4 treatments, each treatment lasts approximately 10 minutes, with intervals of up to 5 weeks apart. The treatments will be conducted in person. Participants will be followed at approximately week 5 post-treatment completion (via phone) at 12 weeks and 24 weeks post treatment completion onsite.~This is a 1726 nanometer laser treatment
Study: NCT06800690

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Estrogen Level
Description: Women had urinary estrogen metabolite levels measured daily to identify both the nadir (menstruation) and the peak (peri-ovulation) of the cycle. Men were also tested at the same time intervals, approximately two-weeks apart.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Estrogen Level
Description: Women had urinary estrogen metabolite levels measured daily to identify both the nadir (menstruation) and the peak (peri-ovulation) of the cycle. Men were also tested at the same time intervals, approximately two-weeks apart.
Study: NCT06801938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perioperative Cystoscopy and Methylene Blue Test
Description: The ability of perioperative methylene blue and cystoscopy versus postoperative cystoscopy to detect complications will be compared in patients.